A detailed history of Campbell Wealth Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Campbell Wealth Management holds 1,813 shares of ABBV stock, worth $304,148. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,813
Previous 3,918 53.73%
Holding current value
$304,148
Previous $672,000 46.73%
% of portfolio
0.03%
Previous 0.22%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$163.84 - $199.33 $344,883 - $419,589
-2,105 Reduced 53.73%
1,813 $358,000
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $28,288 - $32,231
177 Added 4.73%
3,918 $713,000
Q4 2023

Feb 08, 2024

BUY
$137.6 - $154.97 $514,761 - $579,742
3,741 New
3,741 $580,000
Q4 2022

Jan 10, 2023

SELL
$138.31 - $165.87 $30,981 - $37,154
-224 Reduced 8.34%
2,462 $398,000
Q2 2022

Aug 02, 2022

BUY
$137.62 - $174.96 $9,908 - $12,597
72 Added 2.75%
2,686 $411,000
Q4 2021

Jan 27, 2022

BUY
$107.43 - $135.93 $15,792 - $19,981
147 Added 5.96%
2,614 $354,000
Q3 2021

Dec 22, 2022

SELL
$106.4 - $120.78 $23,301 - $26,450
-219 Reduced 8.15%
2,467 $266,000
Q3 2021

Oct 25, 2021

SELL
$106.4 - $120.78 $532 - $603
-5 Reduced 0.2%
2,467 $266,000
Q2 2021

Jul 21, 2021

BUY
$105.21 - $117.21 $260,079 - $289,743
2,472 New
2,472 $278,000
Q3 2020

Nov 02, 2020

SELL
$85.91 - $100.83 $63,487 - $74,513
-739 Closed
0 $0
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $54,220 - $72,555
739 New
739 $73,000
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $170,402 - $200,555
-2,209 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $171,970 - $212,086
2,209 New
2,209 $204,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Campbell Wealth Management Portfolio

Follow Campbell Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Campbell Wealth Management with notifications on news.